Elucidating the Mechanism of Bone Morphogenetic Protein (BMP) -Mediated Sox2 Downregulation in Ovarian Cancer by Shonibare, Zainab Motolani
University of South Carolina 
Scholar Commons 
Theses and Dissertations 
Fall 2019 
Elucidating the Mechanism of Bone Morphogenetic Protein (BMP) 
-Mediated Sox2 Downregulation in Ovarian Cancer 
Zainab Motolani Shonibare 
Follow this and additional works at: https://scholarcommons.sc.edu/etd 
 Part of the Chemistry Commons 
Recommended Citation 
Shonibare, Z. M.(2019). Elucidating the Mechanism of Bone Morphogenetic Protein (BMP) -Mediated 
Sox2 Downregulation in Ovarian Cancer. (Master's thesis). Retrieved from 
https://scholarcommons.sc.edu/etd/5567 
This Open Access Thesis is brought to you by Scholar Commons. It has been accepted for inclusion in Theses and 
Dissertations by an authorized administrator of Scholar Commons. For more information, please contact 
dillarda@mailbox.sc.edu. 
  
Elucidating the mechanism of Bone morphogenetic protein (BMP) -mediated 
Sox2 downregulation in ovarian cancer 
 
by 
 
Zainab Motolani Shonibare 
 
 
Bachelor of Science 
Federal University Oye-Ekiti, 2015 
 
 
Submitted in Partial Fulfilment of the Requirements 
For the Degree of Master of Science in 
Chemistry 
College of Arts and Sciences 
University of South Carolina 
2019 
Accepted by: 
Mythreye Karthikeyan, Director of Thesis 
Maksymilian Chruszcz, Reader 
Cheryl L. Addy, Vice Provost and Dean of the Graduate School 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
©Copyright by Zainab Motolani Shonibare, 2019 
All Rights Reserved. 
iii 
 
  Abstract 
Sex determining region Y-box 2 (Sox2) is a transcription factor essential for 
maintaining self-renewal and pluripotency of undifferentiated embryonic stem 
cells. Sox2 is involved in multiple processes of cancer cells, however, regulation 
of Sox2 expression and the consequences of that regulation in cancer remains 
elusive. Previously, we demonstrated that BMP9/GDF2 is significantly reduced in 
expression in ovarian cancer (OVCA) cells, methylated in patient tumors and, 
promoted anoikis resistance in both breast and OVCA cell lines. In an attempt to 
identify genes downstream of BMP9 that may provide anoikis resistance, 
transcriptomics was performed leading to the identification of Sox2, a 
developmental gene, as being significantly down regulated in response to BMP9. 
I find that Sox2 expression is broadly suppressed by BMP members including 
BMP2, BMP4 and BMP9 both in a time and dose dependent manner. To identify 
the specific ALK receptors utilized for Sox2 repression by BMPs, we used inhibitors 
to the ALK receptors and find specifically that ALK2 and ALK3 are receptors 
utilized by BMPs for Sox2 regulation.  We also examined if Sox2 repression occurs 
via SMAD activation and find that SMAD1 activation is required for BMP-mediated 
Sox2 downregulation. This was validated via sh-RNA based approaches. Data 
from Sox2 promoter reporter assay suggests the involvement of the Sox2 promoter 
as the regulatory region involved in BMP-mediated downregulation, which was
iv 
 
confirmed by expressing Sox2 from a heterologous CMV promoter which failed to 
be repressed by BMP. Furthermore, we find that de novo protein and RNA 
synthesis is required for BMP-mediated Sox2 repression as determined using 
cycloheximide and actinomycin D respectively. My findings indicate that BMP is a 
mediator of Sox2 downregulation in cancer, occurring via SMAD1-dependent 
mechanisms.
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Chapter 1 
Introduction 
Ovarian cancer is the seventh most common cancer worldwide and the 
most lethal of all gynecological cancers1. Epithelial ovarian cancer comprises 90% 
of all ovarian cancers. Most patients with this disease have advanced stage 
disease at the time of diagnosis as a result of the disease already metastasizing 
to other regions in the body. Metastasis from epithelial ovarian cancer can occur 
via the transcoelomic, hematogeneous, or lymphatic route. Of these, 
transcoelomic metastasis is the most common, and is responsible for the greatest 
morbidity and mortality in women with this disease2. This is denoted with the ability 
of the ovarian carcinoma to seed the peritoneal cavity with nests of tumor cells and 
the formation of ascites. The motility and invasive behavior of ovarian carcinoma 
cells are regulated by a repertoire of signaling pathways3.  
Bone Morphogenetic Proteins (BMPs) comprise the largest subgroup of the 
transforming growth factor-β (TGF-β) superfamily of multifunctional cytokines that 
play important roles in the majority of morphogenetic processes during 
development4. BMPs control a diverse range of cellular responses such as 
differentiation, proliferation, apoptosis etc5. Upon ligand (BMP) binding to its type 
I receptor (ALK1, 2, 3 and 6), the type I receptor recruits the type II receptor 
(BMPRII) which has constitutively active receptor kinase activity that transphosph-
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orylates and activates the kinase activity of the type I receptor. Once active, the 
ALK’s phosphorylate the intracellular effector proteins, Smad1/5/8 which complex 
with the common partner, Smad4, to accumulate in the nucleus where it further 
associates with coactivators or corepressors to regulate gene expression6. Various 
BMP members have been shown to reduce or enhance tumorigenesis and 
metastasis. Thus, implicating BMPs as having a dual role both in cancer 
progression and suppression7.  
Sex-determining region Y- box 2 (Sox2) is a transcription factor that interact 
with DNA through a highly conserved HMG domain8, and has a transactivation 
domain at its C terminus9. Sox2 belongs to group B of the Sox family, encoded by 
a single-exon gene on chromosome 3q26.3-q272010. The HMG-domain box 
ensures precise DNA recognition and highly specific DNA binding. Sox proteins 
can bind to ATTGTT or related sequence motifs through their HMG domain, which 
consists of three α helices11,12. Sox2 was initially found to maintain the embryonic 
stem cell pluripotency13. More recently, Sox2 is being shown to be involved in a 
series of malignancies. Numerous studies have shown that Sox2 promotes cell 
proliferation, migration, invasion and tumor metastasis in several cancers14,15. 
Moreover, high expression levels of Sox2 correlate with tumor progression or poor 
prognosis of multiple cancers. Ye. F., et al. found that Sox2 is significantly 
overexpressed in OVCA tissues compared with normal ovary tissues16. These 
findings suggest that Sox2 might act as a tumor promoting gene in OVCA. 
However, how Sox2 expression is regulated, the functional roles and precise 
mechanisms of action of Sox2 in OVCA remains elusive. 
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In a previous study, our lab found that BMP9, a member of the BMP family, 
is significantly reduced in expression in several cancer cell lines, especially ovarian 
cancer, and in patient tumors via epigenetic silencing of the BMP9 promoter by 
methylation17. Therefore, identification of downstream gene targets in which BMPs 
regulate and understanding the molecular mechanisms of BMP regulations on 
downstream genes will be crucial in providing a better insight into combating this 
disease. In this study, we find that Sox2 is a downstream repressed target of BMP. 
We show that BMP-mediated Sox2 downregulation in ovarian cancer cell lines PA1 
and OVCAR3 occurs via SMAD1-dependent mechanism, as well as, identified 
ALK2 as the Type I receptor utilized in Sox2 repression by BMPs. Furthermore, 
we find that BMP-mediated Sox2 downregulation requires new RNA and protein 
synthesis. 
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Chapter 2 
Results 
Characterization of the effect of BMP on Sox2 expression in Ovarian Cancer 
         We previously demonstrated that BMP9/GDF2 is significantly reduced in 
expression in OVCA cells and showed that BMP9 significantly enhances anoikis 
sensitivity in ovarian cancer17. In an attempt to identify genes downstream of BMP9 
that may provide anoikis resistance, we performed microarray analysis and find 
Sox2 to be significantly downregulated in response to BMP9 with about 11-fold 
decrease in gene expression (Figure 2.1A). To validate the microarray data, we 
performed quantitative-Polymerase Chain Reaction (qPCR) and confirmed Sox2 
downregulation in response to BMP9 at the mRNA level (Figure 2.1B). Next, we 
screened a panel of OVCA cells to identify cancer model systems for Sox2 
expression, and find PA1 and OVCAR3 to have the most robust Sox2 expression 
at the protein and mRNA level as indicated by the western blotting and qPCR data, 
while OVCA433 and OVCA420 have the least Sox2 expression in the panel 
(Figure 2.1C). We examined the effect of the broader BMP family members on 
Sox2 expression and find that Sox2 expression is broadly suppressed by BMP 
members including BMP2, BMP4 and BMP9 both at the protein and mRNA level 
in PA1 and OVCAR3 (Figure 2.1D-E) (data not shown for BMP4). Furthermore, we 
performed immunofluorescence to observe changes in Sox2 protein localization in 
response to BMP2 and BMP9. We find that Sox2 is tightly localized in the nucleus 
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and its levels in the nucleus gets significantly reduced in response to BMP2 and 
BMP9 (Data not shown). This finding corroborates the western blotting data, thus, 
confirms that BMP2 and BMP9 downregulates Sox2 protein expression. 
          To determine the dose dependency of BMP2 and BMP9 on Sox2 
expression, we performed a dose course analysis of BMP2 and BMP9 on Sox2 
expression and find 10 nM to be an optimum dose to mediate Sox2 downregulation 
in response to BMP in PA1 and OVCAR3 (Figure 2.2C). To investigate the kinetics 
of Sox2 downregulation in response to BMP at the protein and mRNA level, we 
carried out a time-course analysis of Sox2 expression in response to BMP2 and 
BMP9 in PA1 and OVCAR3. We find that downregulation of Sox2 expression in 
response to BMP begins after 6 hours at the protein and mRNA levels. These 
findings were validated in PA1 and OVCAR3 (Figure 2.2 A-B).  
Role of ALK receptors in BMP-mediated Sox2 repression 
To identify the specific ALK receptors involved in Sox2 repression by BMPs, 
we carried out inhibition assay of the ALK receptors by treating with chemical 
inhibitors which blocks the activity of the receptors in phosphorylating downstream 
SMADs. First, we first confirmed SMAD1/5 and SMAD2/3 activation in response 
to BMP2 and BMP9 by carrying out a time-course analysis of SMAD1/5 
phosphorylation in PA1. Robust SMAD1/5 could be observed as early as 
15minutes in response to treatment with BMP2 and BMP9, while, slight SMAD2/3 
phosphorylation was observed (Figure 2.3). PA1 and OVCAR3 cells were 
pretreated for 1 hr with Dorsomorphin (inhibitor of ALK 2, 3 and 6), SB431542 
(inhibitor of ALK 4, 5 and 7), ML347 (inhibitor of ALK 1, 2) and LDN193189 
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(inhibitor of ALK 2, 3), followed by treatment with BMP2 or BMP9 for 24 hr. We find 
that dorsomorphin partially suppresses BMP-mediated Sox2 downregulation with 
about 60% recovery in Sox2 expression both at the protein and mRNA level and 
completely blocked BMP-induced SMAD1/5 activation in PA1 and OVCAR3. 
SB431542 had no effect on BMP-mediated Sox2 downregulation in PA1 and 
OVCAR3 and this rule out the involvement of ALK 4, 5 and 7 in BMP-mediated 
Sox2 downregulation (Figure 2.4A-B). Interestingly, ML347 significantly 
suppressed BMP9-mediated Sox2 downregulation both at the protein and mRNA 
level and completely blocked BMP9-induced SMAD1/5 activation in PA1 and 
OVCAR3, however, only partially suppressed BMP2-mediated Sox2 
downregulation with about 80% recovery in Sox2 expression and partially block 
BMP2-induced SMAD1/5 activation in PA1 and OVCAR3. Finally, treatment with 
LDN193189 fully suppressed both BMP2- and BMP9- mediated Sox2 
downregulation with total recovery in Sox2 expression both at the protein and 
mRNA level and completely blocked BMP-induced SMAD1/5 activation in PA1 and 
OVCAR3 (Figure 2.4C-D). This data identifies ALK 2/3 as the ALK receptors 
utilized in BMP-mediated Sox2 downregulation in OVCA, as well as suggests a 
role for SMAD1 in Sox2 repression by BMPs. 
BMP-mediated Sox2 downregulation is via SMAD1-dependent mechanisms 
Recent studies showed that BMP members can activate both the canonical 
SMAD1/5-dependent and SMAD-2/3 signaling pathways, therefore, we aimed to 
identify the signaling machinery utilized for BMP-mediated Sox2 downregulation. 
Data from the ALK inhibition studies above indicates that SMAD1 activation is 
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required for BMP-mediated Sox2 repression. Therefore, we confirmed this 
involvement of SMAD1 by making independent knockdown of SMAD1 using 
shRNA -based approach. We find that the effect of BMP on Sox2 expression was 
significantly abrogated by shRNA to SMAD1 when compared to the control cells in 
OVCAR3 (Figure 2.5A). These results confirm the requirement for SMAD1 
activation in BMP-mediated Sox2 downregulation.  
Furthermore, BMP9 and BMP10 form a subgroup within the BMP families 
based on similarities in their primary amino acid sequences, as well as, 
overlapping function in angiogenesis. BMP9 and especially BMP10 were reported 
to utilize an endothelial specific ALK1 receptor which activates SMAD1/5. We 
reported that unlike BMP9, BMP10 cannot activate SMAD1/5 in epithelial cells. 
Thus, we further investigated this requirement for SMAD1/5 activation in BMP-
mediated Sox2 downregulation by examining the effect of BMP10 on Sox2 
expression. We find that BMP10 cannot downregulate Sox2 expression in OVCA 
epithelial cells (Figure 2.1F), thus, confirms our result states that SMAD1 activation 
is required for Sox2 repression by BMPs. 
Effect of non-SMAD pathways on BMP-mediated Sox2 downregulation 
Research has shown that BMP can utilize SMAD and non-SMAD pathways 
to mediate its downstream effects. Here, we investigated the involvement of the 
non-canonical signaling pathway in Sox2 regulation by BMPs. This was done by 
blocking the ‘committed’ intermediates of the non-SMAD pathway - MAP Kinase, 
Wnt, Phosphoinositide 3-Kinase/FAK, Erk, YAP signaling pathways using the 
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following inhibitors: U0126, IWP-4, PF431396, and Verteporfin respectively in 
BMP-mediated Sox2 downregulation. 
We find that treatment with UO126 had no effect on BMP-mediated Sox2 
downregulation while treatment with IWP-4 slightly suppressed BMP-mediated 
Sox2 downregulation (Figure 2.7 A-B). We found this interesting as recent studies 
reports a crosstalk between BMP and wnt signaling pathway. We also showed that 
5 µM IWP-4 was optimum to reduce pLRP6 (committed intermediate) levels to 
basal level (Figure 2.7C). Despite reports of crosstalk between the PI3K pathway 
and BMP, as well as, BMP and Yap pathway, our result indicates that these 
pathways do not play a role in BMP-mediated Sox2 downregulation as treatment 
with PF431396 (PI3K/FAK inhibitor) did not affect BMP-mediated Sox2 
downregulation (Figure 2.8A). Interestingly, treatment with 10 nM verteporfin seem 
to slightly suppress the effect of BMP on Sox2 expression, however, increasing 
the dose of verteporfin to 20 nM showed more strongly that Yap pathway is not 
involved in BMP-mediated Sox2 downregulation (Figure 2.8B). 
Although, BMP has been reported to utilize some non-SMAD dependent 
pathways to mediate its downstream effect, however, our data suggests that BMP-
mediated Sox2 downregulation occurs via SMAD1 dependent mechanism. 
Nonetheless, the involvement of wnt signaling in BMP-mediated Sox2 
downregulation seems very promising yet our data in Figure 2.9C shows that BMP 
slightly activates LRP6 which is a co-receptor for wnt signaling. 
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BMP reduces Sox2 promoter transcriptional activity 
To determine whether Sox2 promoter is involved in BMP-mediated Sox2 
downregulation, we performed luciferase reporter assay using a 1kb pGL3-Sox2 
promoter construct in HEK293 cells. We find that BMP significantly reduces Sox2 
transcriptional activity (Figure 2.6B). We confirmed the role of Sox2 promoter by 
expressing Sox2 from a heterologous CMV promoter in SKOV3 cells, followed by 
treatment with BMP. We find that cell line with the overexpression construct 
(SKOV3-cmv-Sox2OE) resulted in no repression in Sox2 levels in response to 
BMP, when compared to control cells (Figure 2.6A). This data confirms the 
involvement of Sox2 promoter in BMP-mediated Sox2 downregulation. 
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Figure 2.1 Characterization of the effect of BMP members on Sox2 
expression in Ovarian Cancer. (A) Microarray analysis in PA1 cells identifying 
Sox2 as one of the most repressed gene upon treatment with BMP9 and (B) qRT-
PCR validation of the microarray result, (C) (i) Western blot and (ii) qRT-PCR 
screening for Sox2 expression in a panel of OVCA cells. (D-E) Western blot and 
qRT-PCR of the effect of 10 nM BMP2 and BMP9 on Sox2 expression in PA1 and 
OVCAR3 cells. Cells were treated for 24 hr in serum-free media (F) Effect of 
broader BMP members on Sox2 protein expression in PA1. Cells were treated with 
10 nM of the indicated BMP’s for 24 hr in serum-free media. All error bars represent 
the mean ± SEM. ***p<0.001, **p<0.01, *p<0.05. Two-tailed t-tests was used to 
test for significance. 
 
 
 
 
 
  
1
1
 
   
 
Figure 2.2 (Figure 2.1 continued).  (A-B) Time course analysis of effect of 10 nM BMP2 and BMP9 on Sox2 expression 
at the Protein and mRNA level in PA1 and OVCAR3, (C) Dose course of BMP2 and BMP9 on Sox2 expression in PA1 and 
OVCAR3. All error bars represent the mean ± SEM. ***p<0.001, **p<0.01, *p<0.05. One way ANOVA, Bonferroni multiple 
comparison test.
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Figure 2.3 SMAD1/5 activation in response to BMP. Time course of Smad1/5 
and Smad2/3 phosphorylation in PA1 cells in response to 10 nM BMP2 and 
BMP9. Lysates were analyzed by immunoblotting with the indicated antibodies. 
 
 
  
1
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Figure 2.4 Identification of ALK receptors utilized for Sox2 repression by BMP. Western blot and qPCR for (A) PA1 
and (B) OVCAR3 cells pretreated with 5μM Dorsomorphin (ALK 2,3 and 6 inhibitor) and SB431542 (ALK4,5 and 7 
inhibitor) for 1hr, followed by treatment with BMP2 and BMP9 for 24 hr (i-iv). Western blot and qPCR of (C) PA1 and (D) 
OVCAR3 cells pretreated with 3μM ML347 (ALK 1,2 inhibitor) and 0.8μM LDN193189 (ALK 2,3 inhibitor) for 1hr, followed 
by treatment with BMP2 and BMP9 for 24 hr. . All error bars represent the mean ± SEM. ***p<0.001, **p<0.01, *p<0.05. 
One way ANOVA, Bonferroni multiple comparison test.
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Figure 2.5. Role of SMAD1 and SMAD4 in BMP-mediated Sox2 
downregulation. A) OVCAR3 cells transiently expressing shRNA to SMAD1 
(shSMAD1) or Non-targeting control (NTC) in indicated cells for 72 hr. (i) qPCR 
showing expression of SMAD1 to validate knockdown. Values are normalized to 
their Non-targeting control. (ii) Western blot analysis of OVCAR3 cells expressing 
shSMAD1 or NTC, treated with the indicated BMP for 24 hr. (iii) qPCR showing 
relative expression of SMAD1 and (iv) Sox2 in shSMAD1- and NTC- OVCAR3 
cells, followed by treatment with BMP for 24 hr. B) qPCR showing relative 
expression of (i) SMAD4 and (ii) Sox2 in siSMAD4- and NTC- OVCAR3 cells, 
followed by treatment with BMP for 24 hr. All error bars represent the mean ± SEM. 
***p<0.001, **p<0.01, *p<0.05. One way ANOVA, Bonferroni multiple comparison 
test. 
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Figure 2.6. Role of Sox2’s promoter in mediating Sox2  
downregulation by BMP. A) SKOV3 cells stably expressing Sox2  
over-expression (Sox2OE) from a CMV promoter or control (CMV-ctrl)  
vector, were treated with BMP for 24 hr. B) HEK293 cells were transfected  
with 1kb pGL3-Sox2 promoter-reporter construct (500 ng). Luciferase  
reporter activity in the absence or presence of BMP for 24 hr is presented.  
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Figure 2.7 Supplementary figure 1. Western  
blot of PA1 cells pretreated with 5µM U0126  
and 5µM IWP-4 for 1 hr, followed by treatment  
with BMP9 (A) and BMP2 (B) for 24h.  
(C) Immunoblot of lysate for pLRP6 in response  
to treatment with IWP-4. 
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Figure 2.8 Supplementary figure 2. Western blot of  
PA1 cells pretreated with (A) 5 µM PF431396 and  
(B) Verteporfin (dose indicated) for 1 hr, followed by 
treatment with BMP for 24 hr.  
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Chapter 3 
Discussion 
BMP play pleiotropic roles during embryonic development depending on 
their dose, duration of treatment and state of the cell. BMP has been reported to 
play a dichotomous role in tumorigenesis where it could act as a tumor suppressor 
or tumor promoter7. Here, we show for the first time a role for BMP in Sox2 
regulation in OVCA. We showed that Sox2 repression is broadly mediated by 
members of the BMP family - BMP2, BMP4 and BMP9 at the protein and mRNA 
level in OVCA cells, both in a time and dose dependent manner in PA1 and 
OVCAR3. BMP signaling has been known to occur via the canonical SMAD1/5 
signaling pathway, however, recent studies revealed that some members of the 
BMP family can activate both the canonical SMAD1/5 and non-canonical SMAD2/3 
signaling pathway. We find BMP significantly activates Smad1/5 with limited 
activation of Smad2/3 (Figure 2.3).  Biochemical studies using inhibitors to the ALK 
receptors identifies ALK2 and ALK3 receptors as the receptors utilized by BMP to 
mediate Sox2 repression, evidenced as treatment with LDN193189 resulted in 
total inhibition of Sox2 downregulation in response to BMP in PA1 and OVCAR3 
cells (Figure 2.4). Furthermore, Sox2 regulation was found to be via SMAD1-
dependent mechanism using shRNA-based approaches. Knockdown of SMAD1 
suppressed the effect of BMP on Sox2 expression in OVCAR3 cells (Figure 2.5). 
In addition, BMP10, which we had previously reported as unable to activate 
 19 
SMAD1/5 in epithelial OVCA cells as BMP10 preferably binds to ALK1 receptor 
(17), had no effect on Sox2 expression (Figure 2.1F).BMP-mediated Sox2 
downregulation was completely abrogated when cells were pretreated with CHX 
followed by treatment with BMP (Figure 2.7A-B). Similarly, treatment with ActD 
suppressed BMP-mediated Sox2 downregulation (Figure 2.7C). Therefore, these 
results suggest that de novo protein and RNA synthesis is required for BMP-
mediated Sox2 downregulation. 
Furthermore, we find that Sox2 promoter is a regulatory region involved in 
BMP-mediated Sox2 downregulation from our readout of the luciferase promoter-
reporter assay. This was confirmed by the Sox2 overexpression study using a 
heterologous promoter cmv to drive Sox2 expression. Treatment with BMP had no 
effect on Sox2 expression in Skov3-cmv-Sox2, thus, confirming the involvement 
of the promoter region in BMP-mediated Sox2 downregulation (Figure 2.6A). 
Further studies about mechanism of interaction of SMAD1 with epigenetic 
modifiers on the Sox2 promoter will be helpful in providing a better insight into the 
dynamics of the mechanism of action of Smad1 in Sox2 regulation. 
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Chapter 4 
Materials and Methods 
Cell Lines and Culture Conditions 
Ovarian teratoma and epithelial carcinoma cell lines were obtained from 
both Duke Gynecology/Oncology Bank (Durham, NC) and NIH. Authentication was 
carried out at the University of Colorado (Denver, CO) sequencing facility. 
Carcinoma cell lines PA1, OVCAR4, OVCAR5, 41M, IGROV, HEY, A2780, SK-
OV3 and PE01 were cultured in RPMI-1640 (ATCC® 30-2001TM) containing L-
glutamine, 10% FBS and 100U of penicillin-streptomycin while OVCAR3, 
OVCAR420, OVCAR433 were cultured same as above except without penicillin-
streptomycin. HEK293 cells were grown in complete DMEM supplemented with L-
glutamine, 10% fetal bovine serum (FBS) and 100 U of penicillin-streptomycin. Cell 
from patient sample EOC08, EOC10, EOC14, EOC15, EOC17 were obtained from 
Pennsylvania State Hershey medical center (Hershey, PA). All cell lines were 
maintained at 37oC in a humidified incubator at 5% CO2, routinely checked for 
mycoplasma 3 times a year (MycoAlert PLUS mycoplasma detection kit, Lonza, 
Basel, Switzerland) and experiments conducted within 3-6 passages depending 
on the cell line.  
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Antibodies and Reagents  
  Antibodies phospho-SMAD1/5 (#9516), phospho-SMAD2/3 (#8828S), 
SMAD1 (#6944S), SMAD2 (#5678S), SMAD4 (#6944), β-actin (#3700), Sox2 
(#3579) were from Cell Signaling Technology (Danvers, MA). Inhibitors 
dorsomorphin (#p5499), SB431542 hydrate (#S4317), LDN193189 (#SML0559) 
were from Sigma-Aldrich. ML347 (#4945) was from Tocris Bioscience. Leptomycin 
B (SC-358688) was from Santa Cruz. Cycloheximide (#97064-724) was 
purchased from VWR. Actinomycin D (AAJ60148LB) was purchased from Fisher 
Scientific. BMP2, BMP9, Activin and TGFβ1 were from R&D Systems. 
Generation of transient knockdown cells using lentiviral shRNA or siRNA 
and transfection of plasmid DNA 
For transient SMAD1 knockdown, OVCAR3 cells were infected with SMAD1 
shRNA lentivirus or Non-targeting control (NTC) construct (sequence in Table 4.1) 
in the presence of 10µg/mL polybrene (hexadimethrinebromide). Lentiviral shRNA 
plasmids were obtained from Dharmacon and are listed in Table 4.1. Plasmid 
extraction was done using the Zymo® Miniprep kit (Zymo Research, Irvine, CA). 
The lentiviral particles were generated at the COBRE Center for Targeted 
Therapeutics Core Facility (University of South Carolina). For SMAD4 knockdown, 
OVCAR3 cells were transfected with 10nM SMAD4 siRNA or universal negative 
scramble control, purchased from OriGene Technologies (Rockville, MD). 
Transfection was performed using Lipofectamine RNAimax reagent from 
ThermoFisher Scientific (Waltham, MA). The knockdown was confirmed by qPCR
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(sequence in Table 4.2).  Transient DNA transfections were carried out in PA1 
using Lipofectamine 3000 from Life Technologies (Carlsbad, CA). 1kb Sox2 
promoter-luciferase plasmid construct (pGL3-Sox2) was purchased from Addgene 
- #101761 (Watertown, MA). 
RNA isolation and Quantitative Polymerase Chain Reaction (qRT-PCR) 
analysis 
Total RNAs were extracted from cells using Trizol reagent (Invitrogen, 
Carlsbad, CA) and chloroform. RNA was retro-transcribed using 5x iScript Reverse 
Transcription Supermix (#1708840) and the Sso Advanced Universal SYBR Green 
Supermix (Bio-Rad #1725271) from Bio-Rad (Hercules, CA). All expression data 
were normalized to those for RPL13A. qPCR primer sequences are listed in Table 
4.2. 
Luciferase Assay 
HEK293 Cells were transfected with the pGL3-Sox2 promoter reporter 
plasmid for 24h. Treatment with BMP2 or BMP9 (10 nM) was added to the media 
for 24 hours. Cells were collected and lysed in 1 × passive lysis buffer (Promega) 
according to manufacturer’s instructions. To measure luciferase activity, 20 μL of 
lysate was added to 25 μL of Luciferase Assay Reagent (Promega), and 
luminescence was quantitated using a luminometer (Biotek).  
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Immunofluorescence 
Cells were fixed in 4% paraformaldehyde, permeabilized in 0.3% TX-100, 
and blocked with 1% BSA PBS. Primary antibody (1:200) incubation for an hour 
was followed by 30-minute incubation with Alexa Fluor 488 (H+L) (#A11008 Life 
Technologies). After washing, cells were stained with 4′6-diamidino-2-phenylindole 
(Roche). Imaging was performed using an Olympus IX81 motorized inverted 
microscope. 
Statistical analysis 
All in vitro experiments were conducted at least three times and in triplicate 
when applicable or as indicated in figure legends. In vitro experiments were 
analyzed using parametric statistics (analysis of variance global test with 
Bonferroni-corrected 2-tailed Student’s t-tests as post hoc tests) and presented as 
mean ± SEM. In cases where data were normalized to control, one-sample 
Student’s t-test was used with an expected value of 1 or 100% in order to decrease 
the likelihood of a type I error. All statistical analyses were conducted with 
GraphPad Prism Software. 
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Table 4.1. qPCR Primers 
 
1 RPL13A F human: AGA TGG CGG AGG TGC AG.  
RPL13A R human:  GGC CCA GCA GTA CCT GTT TA 
2 Smad1 F human: AAT TCC GGG GGT ATT GGC AG.  
Smad1 R human: AAG TAA CCC AGT CAG CAC CG 
3 Sox2 F human: GCC GAG TGG AAC TTT TGT CG.  
Sox2 R human: GGC AGC GTG TAC TTA TCC TCC T 
 
Table 4.2. shRNA sequence 
SMAD1 
pooled 
sequence 
 
AGAGACTTCTTGGGTGGAA 
GTGTGTTGGTGGATGGTTT 
TCAAGAACCTGTTTAGTTT 
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